Core Insights - Solid Biosciences Inc. reported positive interim data for SGT-003 in the Phase 1/2 INSPIRE DUCHENNE trial, indicating a differentiated clinical profile and good tolerability among 41 participants dosed as of March 18, 2026 [1][4] - The company plans to initiate the Phase 3 IMPACT DUCHENNE trial for SGT-003 in April 2026 and is seeking FDA guidance for a potential accelerated approval pathway [1][2] - Solid has a strong capital position with $187.9 million in cash and equivalents as of December 31, 2025, and completed a $240 million private placement in March 2026, extending its cash runway into H1 2028 [1][2][4] Neuromuscular Pipeline - SGT-003 is designed for Duchenne muscular dystrophy and has shown robust microdystrophin expression and improvements in muscle integrity biomarkers and cardiac function [4][9] - The first participant in the Phase 1b FALCON trial for SGT-212 (Friedreich's Ataxia) has been dosed, with no treatment-related adverse events reported [1][7] - The Phase 1b ARTEMIS trial for SGT-501 (CPVT) has activated clinical sites, with first participant dosing expected in Q2 2026 [1][7] Financial Performance - R&D expenses for Q4 2025 were $38.1 million, up from $30.8 million in Q4 2024, with a total of $140.3 million for the full year 2025 compared to $96.4 million in 2024 [15][19] - General and administrative expenses for Q4 2025 were $11.3 million, compared to $9.1 million in Q4 2024, totaling $38.9 million for the full year 2025 [15][19] - The net loss for Q4 2025 was $49.8 million, compared to a net loss of $42.6 million in Q4 2024, with a total net loss of $174.3 million for the full year 2025 [15][19]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) For the transition period from_________ to _________ Commission File Number 001-38360 Solid Biosciences I ...

Core Insights - Ally Bridge Group NY LLC reduced its stake in Solid Biosciences Inc. by 24.1%, now holding 549,182 shares valued at approximately $3,388,000, representing 2.1% of its investment portfolio [2] - Institutional investors collectively own 81.46% of Solid Biosciences, with several firms increasing their stakes significantly in the second quarter [3] - Insider selling activity includes CFO Kevin Tan and CEO Alexander Cumbo, who sold shares at an average price of $6.44, resulting in ownership decreases of 19.76% and 22.85% respectively [4] Institutional Activity - Bollard Group LLC acquired a new position valued at about $1,761,000 in the second quarter [3] - Geode Capital Management LLC increased its position by 184.5%, now owning 1,510,153 shares worth $7,356,000 after purchasing an additional 979,294 shares [3] - Franklin Resources Inc. raised its stake by 28.9%, owning 1,599,173 shares valued at $7,788,000 after acquiring 358,473 shares [3] Insider Transactions - CFO Kevin Tan sold 26,837 shares for a total of $172,830.28, reducing his ownership to 108,984 shares valued at approximately $701,856.96 [4] - CEO Alexander Cumbo sold 80,258 shares for $516,861.52, leaving him with 270,931 shares valued at around $1,744,795.64 [4] - Over the last three months, insiders sold 597,672 shares valued at $3,816,546, with corporate insiders owning 1.90% of the stock [4] Analyst Ratings - Needham & Company LLC maintains a "buy" rating with a price target of $16.00 [5] - Wedbush reiterates an "outperform" rating with a target price of $14.00 [5] - The average rating for Solid Biosciences is "Moderate Buy" with a price target of $14.70 based on data from MarketBeat [6] Company Overview - Solid Biosciences Inc. is a clinical-stage biotechnology company focused on therapies for Duchenne muscular dystrophy (DMD) [8] - The company's lead investigational therapy, SGT-001, is a micro-dystrophin gene therapy candidate designed to deliver a functional form of the dystrophin gene [9] Stock Performance - Solid Biosciences stock opened at $7.31, with a market cap of $569.52 million and a price-to-earnings ratio of -2.94 [7] - The stock has a 52-week low of $2.41 and a high of $8.72, with a 50-day moving average of $6.24 and a 200-day moving average of $5.73 [7]

Core Insights - Solid Biosciences is a precision genetic medicine company focusing on Duchenne muscular dystrophy (DMD) and other genetic disorders [2][4] - The company is advancing its lead program, known as 003, which targets DMD, alongside programs for Friedreich's ataxia and various cardiac conditions [2][4] Company Overview - Solid Biosciences has developed multiple delivery technologies for gene therapy, including capsids, promoters, and dual plasmids [2] - The company aims to position its DMD program, 003, as a comprehensive solution in the competitive landscape of DMD gene therapy [4] Industry Context - The DMD landscape features numerous gene therapy programs, and Solid Biosciences is actively engaging in discussions to highlight the unique aspects of its offerings [3][4]

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Chrisomalis has extensive experience as a private investor in the Biotech sector, leveraging his Applied Science background to create long-term value in Healthcare [2] - The Biotech Analysis Central service includes over 600 Biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, live chat, and various analysis and news reports to assist Healthcare investors [2] Group 2 - The article does not provide any specific investment recommendations or advice regarding the suitability of investments for particular investors [4] - There is a disclosure stating that the author has no current stock or derivative positions in any mentioned companies and no plans to initiate such positions in the near future [3]

Summary of Solid Biosciences FY Conference Call Company Overview - **Company**: Solid Biosciences (NasdaqGS:SLDB) - **Focus**: Precision genetic medicine, primarily targeting Duchenne muscular dystrophy (DMD) with lead program SGT-003, and additional programs for Friedreich's ataxia and cardiac conditions [2][3] Key Points and Arguments DMD Program and Data Update - **Current Status**: 40 patients dosed in the Phase 1/2 INSPIRE study, with expression data available for 20 patients [4] - **Expression Data**: Achieved 60% mean normal microdystrophin and 63% of muscle fibers showing expression, indicating effective muscle protection [5][6] - **Safety Profile**: No increase in liver biomarkers (AST, ALT) observed, addressing concerns about liver toxicity associated with other treatments [8][9] - **Steroid Regimen**: Reduced high-dose steroid treatment duration from over 60 days to 30 days, improving tolerability for patients [9] Regulatory Strategy - **FDA Alignment**: Plans to meet with the FDA to discuss accelerated approval and the use of natural history data for comparison [14][25] - **Trial Design**: Double-blind placebo-controlled trial design to ensure rigorous data collection and meet international reimbursement standards [19][20][22] Cardiac Focus - **Importance of Cardiac Health**: Emphasized the significance of monitoring cardiac function in DMD patients, as they are at risk for cardiac and respiratory disorders [26][27] - **Cardiac Efficacy**: Early data suggests improvement in ejection fraction and reduction in cardiac troponin levels, indicating potential cardiac benefits from SGT-003 [30][31] Commercialization and Financials - **Cash Position**: Recently raised $240 million, providing a cash runway into the first half of 2028 [36] - **Commercial Strategy**: Plans for direct commercialization in the US and select international markets, positioning SGT-003 as a best-in-class treatment due to its ease of use and dosing regimen [36][38] Additional Important Content - **Patient-Centric Approach**: The company emphasizes listening to patient and family needs, particularly regarding drug safety and tolerability [6][7] - **Functional Data Strategy**: Deliberate withholding of functional data until alignment with the FDA to maintain data integrity and avoid regulatory issues [12][13] - **Video Assessment**: Use of Duchenne Video Assessment to evaluate patient function in real-life settings, showing promising results in reducing compensatory movements [16][17] This summary encapsulates the critical insights from the Solid Biosciences conference call, highlighting the company's strategic direction, clinical data, regulatory plans, and commercialization efforts.

Core Viewpoint - Solid Biosciences Inc. is experiencing a decline in share price following updates on its clinical trial for SGT-003, an investigational gene therapy for Duchenne muscular dystrophy [1] Group 1: Clinical Trial Results - The company reported interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, where 40 participants have been dosed with SGT-003, showing promising results such as robust microdystrophin expression and improvements in muscle integrity [2] - SGT-003 has demonstrated an encouraging safety profile and has been well-tolerated among participants [3] Group 2: Regulatory Pathway - The company plans to meet with the FDA in the first half of 2026 to discuss a potential accelerated approval pathway for SGT-003, which could significantly impact its market position [4] - An update is expected from the company in mid-2026 following a recent Type C meeting with the FDA [4] Group 3: Technical Analysis - The stock is currently trading 18.9% above its 20-day simple moving average (SMA) and 31.6% above its 100-day SMA, indicating a strong short-term trend [5] - Over the past 12 months, shares have increased by 33.87%, and they are closer to their 52-week highs than lows [5] - The RSI is at 70.01, indicating overbought territory, while the MACD is at 0.2936, suggesting bullish momentum [6] Group 4: Analyst Consensus - The stock carries a Buy Rating with an average price target of $14.12, with recent analyst actions indicating a bullish sentiment [7] - Key resistance is noted at $8.50 and key support at $6.50, with Wedbush maintaining a target of $14.00 and Needham a target of $16.00 [8] Group 5: Market Sentiment - The Benzinga Edge signal reveals a strong momentum score, indicating positive market sentiment, but the overbought RSI suggests caution for short-term traders [9] - At the time of publication, Solid Biosciences shares were down 9.72% at $7.38 [9]

Core Insights - Solid Biosciences Inc. reported positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, indicating robust microdystrophin expression and improvements in muscle integrity and cardiac function [1][2][3] Group 1: Clinical Trial Data - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial, which is an open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability, and efficacy of SGT-003 in pediatric participants with Duchenne [1][3] - Interim data showed robust mean vector copies per nucleus and microdystrophin expression, with Day 90 results indicating 60% microdystrophin expression by western blot and 63% microdystrophin-positive fibers by immunofluorescence [5][8] - Improvements in muscle integrity biomarkers were observed, including a 38% reduction in serum creatine kinase (CK) and a 44% reduction in embryonic myosin heavy chain (eMHC) positive fibers at Day 90 [11][10] Group 2: Safety and Tolerability - SGT-003 has been generally well tolerated among participants, with a promising safety profile observed in the trial [4][6] - The treatment regimen involves a low-burden, steroid-only prophylactic immunomodulation approach [4][6] Group 3: Regulatory and Future Plans - The company is pursuing guidance from the FDA on a potential accelerated approval pathway for SGT-003 and plans to have additional meetings in the first half of 2026 [2][15] - Solid Biosciences has reached alignment with the FDA on the study design for the Phase 3 IMPACT DUCHENNE trial, which is set to begin participant dosing in the first quarter of 2026 [14][15] Group 4: Mechanism of Action - SGT-003's microdystrophin construct includes the R16/R17 binding domain, which is crucial for localizing nNOS to muscle, potentially improving blood flow and reducing muscle breakdown [7][18] - The therapy aims to restore key components of the dystrophin-associated protein complex (DAPC), which is critical for muscle integrity [2][9]

Group 1 - Dr. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER), will leave his position in April, which has led to positive sentiment among investors regarding his controversial decisions during his tenure [1][2] - Moderna's shares are trending higher, with the potential for its mRNA-1010 vaccine to qualify for full approval in adults aged 65 and older, potentially avoiding the need for an additional costly efficacy study [3] - Stocks of several companies, including Solid Biosciences Inc. (up 12.15% to $7.57), Capricor Therapeutics Inc. (up 9.07%), Crispr Therapeutics AG (up 2.80% to $58.08), and Sarepta Therapeutics Inc. (up 4.31% to $17.43), have seen increases following the news of Dr. Prasad's departure [3] Group 2 - The resignation of Dr. Prasad could be beneficial for rare disease sponsors seeking to utilize single-arm studies and external controls for regulatory approval, as he was involved in denying an expedited review path for AMT-130 gene therapy [2] - Analysts from William Blair noted that investors are optimistic about the changes in leadership at CBER, which may lead to a more favorable regulatory environment for certain treatments [2]

Capital Raise and Securities Offering - The Company is issuing an aggregate of 14,973,257 shares of Common Stock at a purchase price of $5.61 per share[42] - The Company is also offering pre-funded warrants to purchase an aggregate of 27,807,482 shares of Common Stock, with an exercise price of $0.001 per Warrant Share[42] - The total purchase price for the Pre-Funded Warrants is $5.609 per Warrant Share[42] - The Closing Date for the transaction will occur no later than the fifth Trading Day after the date of the Agreement[43] - Each Investor will receive a number of Shares and Pre-Funded Warrants as specified in Exhibit A attached to the Agreement[46] - The Company will provide registration rights for the Shares and Warrant Shares under the 1933 Act and applicable state securities laws[4] - The Agreement is executed in reliance upon the exemption from securities registration under Section 4(a)(2) of the 1933 Act[4] - The Company is authorized to issue 240,000,000 shares of Common Stock, and all issued shares are fully paid and nonassessable[50] - The Company has no agreements with any Investor for more favorable terms than those set forth in the current agreement[95] - The Company has not conducted any general solicitation or advertising in connection with the offer or sale of its securities[75] - The Securities will be acquired for the Investor's own account and not for resale or distribution in violation of the 1933 Act[98] - Investors acknowledge they can bear the economic risk and complete loss of their investment in the Securities[99] - The Securities are characterized as "restricted securities" under U.S. federal securities laws[101] - Investors understand that the Securities have not been registered under the 1933 Act and may not be transferred unless certain conditions are met[102] - Each Investor is an institutional "accredited investor" as defined under the 1933 Act[103] - The Company must obtain all necessary consents and approvals for the consummation of the purchase and sale of the Placement Securities[115] - The Company shall have filed with Nasdaq a Listing of Additional Shares notice form for the listing of the Shares and the Warrant Shares[116] - The Company is obligated to sell and issue Placement Securities at the Closing, subject to the fulfillment of specific conditions[122] - Each Investor must execute and deliver the Registration Rights Agreement prior to the Closing[124] - The Company will not issue shares of Common Stock or Common Stock Equivalents for 30 days after the Closing Date without consent from Required Investors[133] - The Company agrees to indemnify each Investor against losses, claims, damages, and liabilities arising from breaches of representation or warranty[140] - The Company is responsible for any placement agent's fees or broker's commissions related to the transactions[135] - The Company must ensure that no stop order or suspension of trading is imposed by Nasdaq or any regulatory body[121] - The Company must provide written notice to Investors if any conditions for Closing become incapable of fulfillment[126] - The Company will request the transfer agent to remove restrictive legends from shares sold by Investors under certain conditions[129] - The Company must ensure that the aggregate number of shares issued in connection with unaffiliated third-party transactions does not exceed 10% of the total shares outstanding after Closing[133] Financial Performance and Projections - Solid Biosciences Inc. reported a significant increase in revenue, reaching $50 million for the fiscal year, representing a 25% year-over-year growth[1] - Solid Biosciences Inc. anticipates a revenue guidance of $60 million for the next fiscal year, indicating a projected growth of 20%[1] - The company reported a 10% increase in gross margin, now standing at 65%, due to improved operational efficiencies[1] Research and Development - The company is investing $10 million in R&D for new product development, focusing on gene therapies and innovative treatment solutions[1] - Solid Biosciences Inc. has established partnerships with three leading research institutions to accelerate its product development pipeline[1] Market Expansion and Strategic Initiatives - The company has expanded its user base by 15%, now serving over 200,000 active users across its platforms[1] - Solid Biosciences Inc. plans to enter two new international markets by the end of the next fiscal year, aiming to increase its global footprint[1] - The company has completed a strategic acquisition of a biotech firm for $30 million, enhancing its capabilities in genetic research[1] - Solid Biosciences Inc. has launched a new product line that is expected to generate an additional $15 million in revenue within the first year[1] - The company is implementing a new marketing strategy with a budget of $5 million to enhance brand awareness and customer engagement[1] Compliance and Corporate Governance - The Company has confirmed that it is duly organized and in good standing under the laws of its jurisdiction of incorporation[48] - The Company has taken all necessary corporate actions for the authorization, execution, and delivery of the Transaction Documents[49] - The Company’s subsidiaries are fully owned and in good standing, with no expected Material Adverse Effect from their operations[48] - The financial statements included in SEC Filings comply with applicable accounting requirements and present fairly the consolidated financial position of the Company[71] - The Company is in compliance with applicable Nasdaq continued listing requirements, with no pending or threatened proceedings regarding delisting[73] - The Company has established and maintains disclosure controls and procedures to ensure material information is communicated to its principal executive and financial officers[81] - There have been no material weaknesses in the Company's internal control over financial reporting since the end of the most recent audited fiscal year[81] - The Company is in compliance with all applicable Health Care Laws, including the Federal Food, Drug, and Cosmetic Act and HIPAA[87] - The Company has not received any written notices from Regulatory Authorities requiring termination or modification of any preclinical studies or clinical trials[86] - The Company has implemented reasonable controls to protect the confidentiality and security of sensitive data, with no known breaches or unauthorized accesses[92] - The Company is in compliance with all applicable data privacy laws, including the EU General Data Protection Regulation (GDPR)[93] - The Company has not engaged in any actions designed to manipulate the price of its securities[89] - The Company is not required to register as an "investment company" under the Investment Company Act of 1940[85]